For the Pfizer and BioNTech coronavirus vaccine to be approved by the U.S. FDA, they will have to provide the regulatory body with at least two months of safety data.
New Zealand expects coronavirus vaccine doses for 750,000 people by early 2021 from Pfizer and BioNTech.
The U.S. Government has signed a $1.95 billion deal with Pfizer and BioNTech for their COVID-19 vaccine. The prices PFE and BNTX stocks are moving higher.
Shanghai Fosun Pharmaceutical Industrial Development received the acceptance notice of clinical trial application for the COVID-19 vaccine candidate BNT162b1 created by BioNTech.
BioNTech (BNTX) stock price is moving higher. The surge follows news on Monday that BioNTech and Pfizer received the “fast track” designation status from the Food and Drug Administration for two of their experimental coronavirus vaccines.
Pfizer and BioNTech stocks have jumped in response to receiving ‘Fast Track’ status on their coronavirus vaccine candidates. PFE and BNTX prices are rising.
Following the positive news, Pfizer and BioNTech shares managed to jump 5% and 2.2% accordingly on Wednesday. PFE closed with a 3% rise while BTNX lost 4%.
Initiating human trials is only one step in the long process of proving the safety and efficacy of a new therapeutic. Still, the timeframes to beginning testing for Moderna, BioNTech and CureVac are faster than typical for traditional vaccines.